Cargando…

Clinical and strategic outcomes of metastatic synovial sarcoma on limb

OBJECTIVE: Synovial sarcoma (SS) is one of the most frequent malignant soft-tissue tumors, and nearly 65% arise in the lower extremities. Survival prediction and the risk factors of the patients are poorly understood. Thus, this study examined the survival and prognostic variables of metastatic limb...

Descripción completa

Detalles Bibliográficos
Autores principales: Jami, Sayed Abdulla, Mobarak, Siam Al, Jiandang, Shi, Xi, Zhu, Tanvir, M M Sohel, Monilal, Sonjoy Sutradhar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Qassim Uninversity 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7644453/
https://www.ncbi.nlm.nih.gov/pubmed/33192230
_version_ 1783606459549876224
author Jami, Sayed Abdulla
Mobarak, Siam Al
Jiandang, Shi
Xi, Zhu
Tanvir, M M Sohel
Monilal, Sonjoy Sutradhar
author_facet Jami, Sayed Abdulla
Mobarak, Siam Al
Jiandang, Shi
Xi, Zhu
Tanvir, M M Sohel
Monilal, Sonjoy Sutradhar
author_sort Jami, Sayed Abdulla
collection PubMed
description OBJECTIVE: Synovial sarcoma (SS) is one of the most frequent malignant soft-tissue tumors, and nearly 65% arise in the lower extremities. Survival prediction and the risk factors of the patients are poorly understood. Thus, this study examined the survival and prognostic variables of metastatic limb SS (LSS). METHODS: Clinical data of LSS patients with metastasis at the presentation from 1975 to 2017 were obtained from the Surveillance, Epidemiology, and End Results database program database. Kaplan–Meier method was used to describe the survival curves. Univariate and multivariate Cox regression analysis were conducted to reveal the real prognostic predictors. RESULTS: Male predominance was observed in the metastatic LSS group from a total number of 217 patients. This population was composed of 49.8% not other specified subtype, 32.7% spindle cell subtype, 17.1% biphasic subtype, and 0.5% epithelioid cell subtype. The 3-year overall survival (OS) and cancer-specific survival (CSS) rates of the entire group were 27.2% and 28.3%, respectively. Tumor size <10 cm, surgery, radiotherapy, and chemotherapy were calculated as independent predictors of improved OS and CSS by multivariate analyses. CONCLUSION: SS is still a disease with a poor prognosis. This can increase the survival rate and time by the well-planned treatment.
format Online
Article
Text
id pubmed-7644453
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Qassim Uninversity
record_format MEDLINE/PubMed
spelling pubmed-76444532020-11-13 Clinical and strategic outcomes of metastatic synovial sarcoma on limb Jami, Sayed Abdulla Mobarak, Siam Al Jiandang, Shi Xi, Zhu Tanvir, M M Sohel Monilal, Sonjoy Sutradhar Int J Health Sci (Qassim) Original Article OBJECTIVE: Synovial sarcoma (SS) is one of the most frequent malignant soft-tissue tumors, and nearly 65% arise in the lower extremities. Survival prediction and the risk factors of the patients are poorly understood. Thus, this study examined the survival and prognostic variables of metastatic limb SS (LSS). METHODS: Clinical data of LSS patients with metastasis at the presentation from 1975 to 2017 were obtained from the Surveillance, Epidemiology, and End Results database program database. Kaplan–Meier method was used to describe the survival curves. Univariate and multivariate Cox regression analysis were conducted to reveal the real prognostic predictors. RESULTS: Male predominance was observed in the metastatic LSS group from a total number of 217 patients. This population was composed of 49.8% not other specified subtype, 32.7% spindle cell subtype, 17.1% biphasic subtype, and 0.5% epithelioid cell subtype. The 3-year overall survival (OS) and cancer-specific survival (CSS) rates of the entire group were 27.2% and 28.3%, respectively. Tumor size <10 cm, surgery, radiotherapy, and chemotherapy were calculated as independent predictors of improved OS and CSS by multivariate analyses. CONCLUSION: SS is still a disease with a poor prognosis. This can increase the survival rate and time by the well-planned treatment. Qassim Uninversity 2020 /pmc/articles/PMC7644453/ /pubmed/33192230 Text en Copyright: © International Journal of Health Sciences http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Jami, Sayed Abdulla
Mobarak, Siam Al
Jiandang, Shi
Xi, Zhu
Tanvir, M M Sohel
Monilal, Sonjoy Sutradhar
Clinical and strategic outcomes of metastatic synovial sarcoma on limb
title Clinical and strategic outcomes of metastatic synovial sarcoma on limb
title_full Clinical and strategic outcomes of metastatic synovial sarcoma on limb
title_fullStr Clinical and strategic outcomes of metastatic synovial sarcoma on limb
title_full_unstemmed Clinical and strategic outcomes of metastatic synovial sarcoma on limb
title_short Clinical and strategic outcomes of metastatic synovial sarcoma on limb
title_sort clinical and strategic outcomes of metastatic synovial sarcoma on limb
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7644453/
https://www.ncbi.nlm.nih.gov/pubmed/33192230
work_keys_str_mv AT jamisayedabdulla clinicalandstrategicoutcomesofmetastaticsynovialsarcomaonlimb
AT mobaraksiamal clinicalandstrategicoutcomesofmetastaticsynovialsarcomaonlimb
AT jiandangshi clinicalandstrategicoutcomesofmetastaticsynovialsarcomaonlimb
AT xizhu clinicalandstrategicoutcomesofmetastaticsynovialsarcomaonlimb
AT tanvirmmsohel clinicalandstrategicoutcomesofmetastaticsynovialsarcomaonlimb
AT monilalsonjoysutradhar clinicalandstrategicoutcomesofmetastaticsynovialsarcomaonlimb